Critical Assessment of G Protein-Biased Agonism at the μ-Opioid Receptor
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
G protein-biased agonists of the μ-opioid receptor (MOPr) have been proposed as an improved class of opioid analgesics. Recent studies have been unable to reproduce the original experiments in the β-arrestin2-knockout mouse that led to this proposal, and alternative genetic models do not support the G protein-biased MOPr agonist hypothesis. Furthermore, assessment of putatively biased ligands has been confounded by several factors, including assay amplification. As such, the extent to which current lead compounds represent mechanistically novel, extremely G protein-biased agonists is in question, as is the underlying assumption that β-arrestin2 mediates deleterious opioid effects. Addressing these current challenges represents a pressing issue to successfully advance drug development at this receptor and improve upon current opioid analgesics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeWire, S. M., Yamashita, D. S., Rominger, D. H., Liu, G., Cowan, C. L., Graczyk, T. M., Chen, X.-T., Pitis, P. M., Gotchev, D., Yuan, C., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201616 · Cited by 647 · cited 2×
“Putatively G protein-biased compounds oliceridine [6], PZM21 [8], mitragynine pseudoindoxyl [9], and SR170178 [7], were all initially assessed to have comparable efficacy to morphine for G protein activation.”
BackgroundExploring the opioid system by gene knockout
Kieffer, B. L., & Gavériaux-Ruff, C. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00008-4 · Cited by 620 · cited 2×
“Opioid-induced respiratory depression is themajor cause of overdose death, andmultiple genetic knockout studies have shown that it results from activation of MOPr rather than δ- or κ-opioid receptor subtypes (DOPr and KOPr) or the opioid-related nociceptin/orphanin FQ receptor (NOPr) [7,11,12], as does inhibition of g…”
BackgroundBias factor and therapeutic window correlate to predict safer opioid analgesics
Schmid, C. L., Kennedy, N. M., Ross, N. C., Lovell, K. M., Yue, Z., Morgenweck, J., Cameron, M. D., Bannister, T. D., & Bohn, L. M. (2017) · Cell · doi:10.1016/j.cell.2017.10.035 · Cited by 567 · cited 5×
“The lack of effect of β-arrestin2 knockout on fentanyl, methadone, or etorphine acute antinociception is surprising, given that these are high-efficacy agonists that robustly induce the recruitment of β-arrestin2 to the MOPr [7,39,51].”
BackgroundInfluentialViscusi, E. R., Skobieranda, F., Soergel, D. G., Cook, E., Burt, D. A., & Singla, N. (2019) · Journal of Pain Research · doi:10.2147/jpr.s171013 · Cited by 167 · cited 2×
“The prototypical such agonist, oliceridine (TRV130), has proceeded to Phase III clinical trials [3], and was recently approved in the USA for use in acute pain.”
BackgroundAltarifi, A. A., David, B., Muchhala, K. H., Blough, B. E., Akbarali, H., & Negus, S. S. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116689257 · Cited by 166 · cited 1×
“In regard to abuse-related effects, volunteers rated oliceridine similarly to morphine in a drug effects questionnaire [77], and, in rodents, both the self-administration of, and the facilitation of, intracranial self-stimulation induced by oliceridine was similar to other opioids [79,80].”
BackgroundVasudevan, L., Vandeputte, M., Deventer, M., Wouters, E., Cannaert, A., & Stove, C. P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113910 · Cited by 55 · cited 2×
“In assays in which these amplification confounds have been addressed, lead compounds, such as oliceridine and PZM21, as well as buprenorphine, are not observed to be significantly G protein biased [48,51,53] (Figure 2E,F), demonstrating that previous descriptions of biased agonism have been largely driven by system pa…”
Background
Cited by
Humphreys, K., Shover, C. L., Andrews, C. M., Bohnert, A. S. B., Brandeau, M. L., Caulkins, J. P., Chen, J. H., Cuéllar, M.-F., Hurd, Y. L., Juurlink, D. N., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02252-2 · Cited by 421
Vandeputte, M. M., Van Uytfanghe, K., Layle, N. K., St. Germaine, D. M., Iula, D. M., & Stove, C. P. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00064 · Cited by 161
Breathing Rhythm and Pattern and Their Influence on Emotion
Ashhad, S., Kam, K., Del Negro, C. A., & Feldman, J. L. (2022) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-090121-014424 · Cited by 161
Mechanisms of opioid-induced respiratory depression
Baldo, B. A., & Rose, M. A. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03300-7 · Cited by 74
Low Intrinsic Efficacy Alone Cannot Explain the Improved Side Effect Profiles of New Opioid Agonists
Stahl, E. L., & Bohn, L. M. (2022) · Biochemistry · doi:10.1021/acs.biochem.1c00466 · Cited by 55
Metadata
- Authors
- Gillis, A., Kliewer, A., Kelly, E., Henderson, G., Christie, M. J., Schulz, S., & Canals, M.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 41
- Issue
- 12
- Pages
- 947-959
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W3093777800
- Cited by
- 159
- References
- 6
- FWCI
- 1.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.